Categories
BLOG

buspar and weed

Drug Interactions between BuSpar and cannabis

This report displays the potential drug interactions for the following 2 drugs:

  • BuSpar (buspirone)
  • cannabis

Interactions between your drugs

busPIRone

cannabis (Schedule I substance)

Applies to: BuSpar (buspirone) and cannabis

Using busPIRone together with cannabis (Schedule I substance) may increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

busPIRone

Applies to: BuSpar (buspirone)

You should avoid the use of alcohol while being treated with busPIRone. Alcohol can increase the nervous system side effects of busPIRone such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. Patients receiving busPIRone should preferably avoid the consumption of large amounts of grapefruits and grapefruit juice. If this is not possible, the busPIRone dose should be taken at least 2 hours before or 8 hours after grapefruit or grapefruit juice. Large amounts of grapefruit and grapefruit juice may cause increased levels of busPIRone in your body. This can lead to increased adverse effects such as drowsiness. Talk to your doctor or pharmacist if you have any questions or concerns.

cannabis (Schedule I substance)

Applies to: cannabis

Alcohol can increase the nervous system side effects of cannabis (Schedule I substance) such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with cannabis (Schedule I substance). Do not use more than the recommended dose of cannabis (Schedule I substance), and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See Also

  • BuSpar Drug Interactions
  • Buspar General Consumer Information
  • Cannabis Drug Interactions
  • Drug Interactions Checker
Drug Interaction Classification
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some mixtures of medications can lead to serious and even fatal consequences.

A Moderate Drug Interaction exists between BuSpar and cannabis. View detailed information regarding this drug interaction.

Buspirone, Stress, and Attentional Bias to Marijuana Cues

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
  • Study Details
  • Tabular View
  • Study Results
  • Disclaimer
  • How to Read a Study Record

This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is to attenuate the influence of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone.

Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias.

Condition or disease Intervention/treatment Phase
Cannabis Use Disorder Drug: Buspirone Drug: Placebo Phase 2

For nearly 40 years marijuana has remained the most widely used illicit drug in the US, with more than 50% of first-time users

Layout table for study information

Study Type : Interventional (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Buspirone, Stress, and Attentional Bias to Marijuana Cues
Study Start Date : June 2013
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:

  • 20-44 Normal Range
  • 45-59 Mild to Moderate Anxiety Levels
  • 60-74 Marked to Severe Anxiety Levels
  • 75-80 Extreme Anxiety Levels

The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:

  • 20-44 Normal Range
  • 45-59 Mild to Moderate Anxiety Levels
  • 60-74 Marked to Severe Anxiety Levels
  • 75-80 Extreme Anxiety Levels

The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:

  • 20-44 Normal Range
  • 45-59 Mild to Moderate Anxiety Levels
  • 60-74 Marked to Severe Anxiety Levels
  • 75-80 Extreme Anxiety Levels

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study: 18 Years to 45 Years (Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
  • Marijuana substance use disorder based on a score of ≥ 13 on the Cannabis Use Disorders Identification Test – Revised (CUDIT-R)
  • a score of ≥ 4 on the Cannabis Abuse Screening Test (CAST)
  • meeting criteria for a marijuana substance use disorder based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)
  • Current DSM-IV Axis I disorder other than marijuana use disorder
  • serious medical illness requiring ongoing medical treatment, which could affect the central nervous system, or any other medical contraindication (e.g., renal, cardiovascular, pulmonary, blood) as determined by medical screening
  • a positive pregnancy test or breast feeding (females)
  • concomitant use of prescription medications that could affect the central nervous system
  • active suicidal ideation or Beck Depression Inventory II score greater than 19
  • positive urine drug screen for drugs other than marijuana or positive breath alcohol screen
  • Shipley-2 test of cognitive aptitude score outside 2 SD units of the published composite score average
  • smoking > 10 nicotine cigarettes per day / Fagerstrom Score > 4
  • taking meds known to have significant drug interactions with buspirone.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Buspirone, Stress, and Attentional Bias to Marijuana Cues The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does